Impact of Hormone Receptor Status and Ki-67 Expression on Disease-Free Survival in Patients Affected by High-risk Endometrial Cancer.
暂无分享,去创建一个
C. Marchetti | P. Benedetti Panici | M. Schiavi | V. Colagiovanni | F. Tomao | L. Muzii | I. Palaia | G. Perniola | V. Di Donato | A. Musella | I. Pecorella | V. Iacobelli | M. Monti
[1] M. Köbel,et al. Progesterone receptor expression is associated with longer overall survival within high-grade histotypes of endometrial carcinoma: A Canadian high risk endometrial cancer consortium (CHREC) study. , 2016, Gynecologic oncology.
[2] Weiwei Shan,et al. Predicting Lymph Node Metastasis in Endometrial Cancer Using Serum CA125 Combined with Immunohistochemical Markers PR and Ki67, and a Comparison with Other Prediction Models , 2016, PloS one.
[3] P. Goodfellow,et al. Estrogen receptor-alpha as a predictive biomarker in endometrioid endometrial cancer. , 2016, Gynecologic oncology.
[4] E. Darai,et al. Endometrial cancer , 2016, The Lancet.
[5] J. Ledermann,et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[6] J. Lopes,et al. Endometrial Endometrioid Carcinoma Metastases Show Decreased ER-Alpha and PR-A Expression Compared to Matched Primary Tumors , 2015, PloS one.
[7] Wei Zhang,et al. Prognostic role of hormone receptors in endometrial cancer: a systematic review and meta-analysis , 2015, World Journal of Surgical Oncology.
[8] C. Mathers,et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.
[9] Bin Li,et al. Expression of ER, PR, C-erbB-2 and Ki-67 in Endometrial Carcinoma and their Relationships with the Clinicopathological Features. , 2015, Asian Pacific journal of cancer prevention : APJCP.
[10] V. Torri,et al. Secondary analyses from a randomized clinical trial: age as the key prognostic factor in endometrial carcinoma. , 2014, American journal of obstetrics and gynecology.
[11] S. Goldman,et al. Distribution of estrogen and progesterone receptors isoforms in endometrial cancer , 2014, Diagnostic Pathology.
[12] T. Hachisuga,et al. Expression of Estrogen Receptor-&agr; as a Prognostic Factor in Patients With Uterine Serous Carcinoma , 2014, International Journal of Gynecologic Cancer.
[13] X. Matías-Guiu,et al. Prognostic biomarkers in endometrial and ovarian carcinoma , 2014, Virchows Archiv.
[14] J. Marcickiewicz,et al. Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial. , 2013, European journal of cancer.
[15] E. Laas,et al. Histological and immunohistochemical profiles predict lymph node status in women with low-intermediate risk endometrial cancer. , 2013, Gynecologic oncology.
[16] F. Pontén,et al. Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma. , 2013, Gynecologic oncology.
[17] J. Trovik,et al. Markers for individualised therapy in endometrial carcinoma. , 2012, The Lancet. Oncology.
[18] Andrea J. O'Hara,et al. The genomics and genetics of endometrial cancer. , 2012, Advances in genomics and genetics.
[19] P. Benedetti‐Panici,et al. New classification system of radical hysterectomy: emphasis on a three-dimensional anatomic template for parametrial resection. , 2011, Gynecologic oncology.
[20] A. Ashworth,et al. Emerging therapeutic targets in endometrial cancer , 2011, Nature Reviews Clinical Oncology.
[21] R. Broaddus,et al. Molecular Clustering Based on ERα and EIG121 Predicts Survival in High-Grade Serous Carcinoma of the Ovary/Peritoneum , 2010, Modern Pathology.
[22] D. Chakravarty,et al. Steroid receptors, HER2/neu and Ki-67, in endometrioid type of endometrial carcinoma: Correlation with conventional histomorphological features of prognosis. , 2010, Acta histochemica.
[23] M. Procházka,et al. Selected Immunohistochemical Prognostic Factors in Endometrial Cancer , 2010, International Journal of Gynecologic Cancer.
[24] Carol L. Brown,et al. Sentinel lymph node mapping for grade 1 endometrial cancer: is it the answer to the surgical staging dilemma? , 2009, Gynecologic oncology.
[25] I. Jonassen,et al. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation , 2009, Proceedings of the National Academy of Sciences.
[26] H. Hollema,et al. Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer. , 2009, Gynecologic oncology.
[27] M. Parmar,et al. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study , 2009, The Lancet.
[28] Meenakshi Singh,et al. Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study. , 2007, Gynecologic oncology.
[29] H. Sommer,et al. Prognostic significance of oestrogen receptor alpha (ERalpha) and beta (ERbeta), progesterone receptor A (PR-A) and B (PR-B) in endometrial carcinomas. , 2007, European journal of cancer.
[30] T. Iwasaka,et al. Prognostic significance of progesterone receptor immunohistochemistry for lymph node metastases in endometrial carcinoma. , 1999, Gynecologic oncology.
[31] L. Akslen,et al. Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[32] T. Iwasaka,et al. Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma. , 1998, Gynecologic oncology.
[33] R. Kurman,et al. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses. , 1997, Verhandlungen der Deutschen Gesellschaft fur Pathologie.
[34] G. Greene,et al. Estrogen receptor immunocytochemistry in endometrial carcinoma: a prognostic marker for survival. , 1996, Gynecologic oncology.
[35] H. Fox,et al. Type I and Type II estrogen and progesterone binding sites in endometrial carcinomas: their value in predicting survival , 1992, International Journal of Gynecologic Cancer.